How Investors Are Reacting To Boston Scientific (BSX) Recall Wave After Strong Mid‑Year Results

• In late July 2026, Boston Scientific reported higher quarterly and half‑year sales and earnings, then in August disclosed multiple voluntary Class II recalls affecting FARASTAR pulsed field ablation generators, FARADRIVE steerable sheaths and the TheraSphere 360 Y‑90 Management Platform software across US and international markets.
• While most affected FARASTAR units were limited in number and linked to labeling discrepancies, the FARADRIVE sheath recalls involve hundreds of thousands of globally distributed devices tied to a valve‑damage risk that requires changes in device preparation technique to reduce the chance of air embolism.
• Next, we’ll consider how this combination of guidance cuts and large-scale FARADRIVE safety-related recalls may reshape Boston Scientific’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Boston Scientific Investment Narrative Recap

To own Boston Scientific today, you need to believe its broad cardiovascular and MedSurg portfolio can keep compounding earnings despite near term headwinds in Electrophysiology and WATCHMAN. The FARADRIVE safety‑related Class II recalls and FARASTAR labeling issues introduce additional execution and reputational risk around one key growth area, but they do not yet clearly alter the central near term catalyst, which remains management’s ability to stabilize EP growth while preserving margins.

The most relevant recent announcement alongside these recalls is Boston Scientific’s cut to 2026 sales guidance to roughly 5.5% to 6.5% growth and a softer 3% to 5% outlook for Q3. Coming just before large scale FARADRIVE recalls, this reset already lowered expectations for EP and WATCHMAN, and it frames how investors may reassess the risk that product quality issues and slower procedure growth could pressure both revenue and Boston Scientific’s long term margin ambitions.

Yet behind the headline growth story, the scale of the FARADRIVE recalls raises fresh questions that investors should be aware of around...

Read the full narrative on Boston Scientific (it's free!)

Boston Scientific’s narrative projects $25.8 billion revenue and $4.9 billion earnings by 2029. This requires 7.8% yearly revenue growth and about a $1.3 billion earnings increase from $3.6 billion today.

Uncover how Boston Scientific's forecasts yield a $72.25 fair value, a 47% upside to its current price.

Exploring Other Perspectives

Before these recalls, the most optimistic analysts were assuming revenue could reach about US$28.0 billion and earnings about US$5.5 billion by 2029, while also counting on sustained pulsed field ablation strength. You can see how this is a much more optimistic story than consensus, and recent safety events may force a rethink of just how smoothly that path plays out.

Explore 8 other fair value estimates on Boston Scientific - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com